logo image

Infliximab information from DrugsUpdate  

See Available Brands of Infliximab in India

Infliximab, an anti-arthritic drug, is prescribed for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis and Crohn’s disease. The drug usually prescribed in treatment-resistant cases. Infliximab is an anti-TNF-alpha monoclonal antibody (biologic) that blocks the action of pro-inflammatory mediators in the pathogenesis of disorders.

Pharmacodynamics

Higher plasma levels of TNF-alpha is linked with inflammation that results in expression of cell adhesion molecules such as Intercellular adhesion molecule 1 (ICAM-1), E-selectin, chemoattraction molecules and matrix metalloproteinase (MMP). The action of Infliximab blocks the binding of TNF-alpha with the active site of receptors that result in decreased levels of Interleukin-6, CRP and activated T-cells in inflamed areas.

Pharmacokinetics

After IV infusion of Infliximab, the drug achieved dose-dependent serum concentration, and it is linear. However, the Vss at steady state is dose-independent. The median half-life of Infliximab varies, and depends on the disorders. No systemic accumulation of Infliximab has been reported, and no age or gender related clearance has been observed. No dose adjustments are needed in patients with hepatic and renal impairments.

Infliximab Indications / Infliximab Uses

Infliximab can cause jaundice-like reactions, unexplained satiety, night sweats, fatigue, infections, easy bruising, epigastric pain, convulsions, painful micturition, myalgia, vision changes, cough, numbness or tingling, flushing, mild skin rashes, abdominal pain and headache.

Infliximab Adverse Reactions / Infliximab Side Effects

No information available

Precautions

Increased risk of lymphoma is reported with Infliximab treatment in autoimmune disorder patients. Caution should be exercised while travelling to tuberculosis endemic areas. Avoid contact with TB patients. Infliximab is contraindicated in patients with immune disorders, seizures, diabetes, recent infections, other heart problems, multiple sclerosis, Guillain-Barre syndrome, COPD or history of cancer.

Special Precautions

No information available

Other Drug Interactions

Infliximab may interact with vaccines like BCG (Bacille-Calmette Guerin), psoriasis medications including phototherapy, mercaptopurine and azathioprine.

Other Interactions

No information available

Dosage

Crohn's Disease

The recommended adult dose of Infliximab is 5 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 5 mg/kg every 8 weeks thereafter. In drug unresponsive cases, the dosage can be increased up to 10 mg/kg. In case of progression even after 14 weeks treatment, the treatment should be discontinued.



Ulcerative Colitis

The recommended adult dose of Infliximab is 5 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 5 mg/kg every 8 weeks thereafter.



Rheumatoid Arthritis

The recommended adult dose of Infliximab is 3 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 3 mg/kg every 8 weeks thereafter. In moderate to severe forms, combined therapy with methotrexate should be considered in accordance with clinical response.



Ankylosing Spondylitis

The recommended adult dose of Infliximab is 5 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 5 mg/kg every 6 weeks thereafter.



Psoriatic Arthritis

The recommended adult dose of Infliximab is 5 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 5 mg/kg every 8 weeks thereafter. The treatment can be either monotherapy or as a combined therapy with methotrexate.



Plaque Psoriasis

The recommended adult dose of Infliximab is 5 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 5 mg/kg every 8 weeks thereafter.



Pediatric Ulcerative Colitis

For children (6 years and over), the recommended adult dose of Infliximab is 5 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 5 mg/kg every 8 weeks thereafter.



Pediatric Crohn's Disease

For children (6 years and over), the recommended adult dose of Infliximab is 5 mg/kg, IV at 0, 2 and 6 weeks with a maintenance dose of 5 mg/kg every 8 weeks thereafter.

Food(before/after)

Information not available

List of Contraindications

Infliximab and Pregnancy

USFDA pregnancy category B. Infliximab may not cause harm to an unborn foetus. Before Infliximab treatment, the patient should discuss with the physician, if they are planning for a pregnancy.

Infliximab and Lactation

It is unclear whether the drug could pass through the breast milk to a breast feeding a baby. Consult your physician before taking Infliximab, if you are nursing mother.

Infliximab and Children

Infliximab is contraindicated in children younger than 6 years old.

Infliximab and Geriatic

Information not available

Infliximab and Other Contraindications

Information not available

Storage

Store at 20-25°C.

Lab interference

Store at 20-25°C.

Infliximab brands in India:

Remicade

© 2011-2018 DrugsUpdate.com. Disclaimer | Site Map

Feedback